^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Published date:
10/16/2023
Excerpt:
Responses were observed in pts with FGFR1 and FGFR2 fusions….Erda demonstrated robust and clinically meaningful activity in pancreatic cancer pts with FGFRalt.
Trial ID:
